Y-mAbs Therapeutics Plunges 15.13% Amid Earnings Reassessment

On March 26, 2025, Y-mAbs Therapeutics experienced a significant drop of 15.13% in pre-market trading, reflecting a notable decline in investor sentiment.

Y-mAbs Therapeutics is anticipated to see earnings growth in the upcoming year, with projections indicating a shift from a loss of $0.65 per share to a reduced loss of $0.59 per share. This positive outlook on earnings could be a contributing factor to the recent market movements, as investors reassess the company's financial health and future prospects.

Shareholders of Y-mAbs Therapeutics have faced substantial losses, with the stock dropping by 14% over the past week. This decline has resulted in a cumulative loss of 74% for investors, highlighting the volatility and challenges the company is currently navigating. The significant drop in stock price may be attributed to various factors, including market sentiment, regulatory developments, or changes in the company's strategic direction.